Prevalence of Clonal Hematopoiesis (CH) in neuroendocrine tumor (NET) patients prior to Lutetium 177 dotatate therapy (Lu177) and the risk of cytopenia – A prospective study of 37 patients

#3827

Introduction: Lu177 has shown efficacy in advanced NET but with significant hematologic toxicity, including therapy-related myeloid neoplasm (t-MN). CH is defined by acquisition of somatic mutations in hematopoietic stem cells with potential for expansion over time.

Aim(s): In this study, we aimed to assess: 1) the prevalence of CH in patients NET planned for Lu177; 2) the incidence of cytopenia in NET patients treated with lu177 based on the CH status at baseline.

Materials and methods: Pre-Lu177 blood samples were prospectively collected from 37 NET patients with planned Lu177. Genomic DNA from mononuclear cells was analysed for CH using a custom panel targeting 229 genes to a targeted depth of >1000X.

Conference:

Presenting Author: Sonbol M

Authors: Sonbol M, Kusne Y, Lasho T, Elsabbagh Z, Mangaonkar A,

Keywords: clonal hematopoiesis, neuroendocrine, PRRT, Lu177, t-MN, CHIP,